Clonal competition with alternating dominance in multiple myeloma.
about
Intratumor heterogeneity: evolution through space and timeTreatment of relapsed and refractory multiple myelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityV. Molecular classification and risk stratification of myelomaTumour heterogeneity and the evolution of polyclonal drug resistanceMolecular pathogenesis of multiple myeloma: basic and clinical updatesClonal evolution in hematological malignancies and therapeutic implicationsPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolutionRecent advances in understanding multiple myelomaTowards Stratified Medicine in Plasma Cell MyelomaThe myeloma stem cell concept, revisited: from phenomenology to operational termsAnalogies in Oncology: Explanations Made EasierTracking genomic cancer evolution for precision medicine: the lung TRACERx studyThe causes and consequences of genetic heterogeneity in cancer evolutionPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.Consolidation in multiple myeloma - current status and perspectivesImpact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationSubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization.Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation.Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data.A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.TPL2 kinase regulates the inflammatory milieu of the myeloma nicheA DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyZebrafish as a model to assess cancer heterogeneity, progression and relapse.The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaThe role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeImplications of heterogeneity in multiple myeloma.Intratumor heterogeneity alters most effective drugs in designed combinations.Serial exome analysis of disease progression in premalignant gammopathies.Minor clone provides a reservoir for relapse in multiple myelomaExpanding the computational toolbox for mining cancer genomes.Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Cancer heterogeneity: implications for targeted therapeutics.A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
P2860
Q24598678-B3B6292C-3C43-4448-94D2-2FB86F0E40A6Q26749180-829CB0BE-CA19-4BCC-BE27-17E62070EC4AQ26771331-1423DAB1-325E-4EFB-8B0D-AB16EE0FA312Q26861396-AF59AD71-3138-4644-A23C-2983235BB090Q26866803-960DEB08-7CB2-479E-B374-5B447D09973AQ27026205-B2E1A6E5-41D9-4A9D-8A26-1D095653A0C2Q27027655-F1528CF1-9978-4B06-B11B-2832C6F2862FQ27027729-ECB3E3CA-83C7-4A5D-A45A-1ABB0AC47DD3Q27316833-D4435309-3895-4740-9153-94E998DC7C6AQ27321859-0D969030-2F96-4817-BE33-0C176602B7C4Q28070331-38243A93-9E46-4954-8EDB-3B930A923082Q28074994-133BC229-7E2C-401F-B0FC-F95E2B4C3DB3Q28076070-07186AF5-539F-44B7-A619-A5A5F8CA4E92Q28087035-523A00FE-2AA0-4AA8-AC5D-F1C11AB35D26Q28655985-553BBFA1-EE42-4C91-9D2E-D33DACA794D8Q29615848-3F4753C1-81C7-4667-A10B-F8A04AABC625Q30365539-A7141C2C-256E-4D79-98F9-8FB4BE7E515FQ30369423-C6732B1B-7A45-4430-820A-B5737A42B20DQ30369607-0C36A77A-63EA-45E8-9DFE-2D11916CD39BQ30410213-F61DE87F-5E7D-48B3-AC21-3F976F5470FFQ30455659-B721776F-51F3-4F3D-B37A-A8F8ED823BB6Q30856576-25A96BC4-311F-4FC3-B0DC-230A5C50DC08Q31006978-44253BF4-558C-417F-9BD1-549C66171303Q33418705-291A5AD3-12EF-4D8F-96C6-592B98651DFEQ33667666-D436B4EE-E392-4A4C-B7E2-7A8F298BDB62Q33714724-FB7CBEC0-E83A-4F7F-9E5E-F63E8A5820FEQ33757020-A7227C5D-C9BA-4FF0-B3DE-13989E104F1FQ33814223-CC6CA72C-2D5B-46E1-8F85-2EF38E7AC31DQ33838260-870F0B60-17DD-4B79-894E-F775A096E5B8Q33913152-1AADB40A-D344-41F4-85F6-2AA2FDEBF99EQ33914824-7FBED31C-BAF1-4AA4-9356-C36E70257F43Q33972115-1D6F50BA-0C7F-4D1D-879E-20331ACF078FQ34079934-C62BC435-4696-4EC0-BE49-2AAE5EA8825EQ34147170-1771330B-2444-4F0F-91B9-B38AE4311373Q34207474-1CB0C407-8BF3-4A2F-9A07-67812490CA97Q34256144-5EE7B299-05D9-425A-9D80-A4198970D581Q34316559-FA3C6FD6-E64B-4FEE-B3F3-59285B2F171AQ34321565-014A3A03-49E7-40AD-87B3-AECDB99596CAQ34374783-CA29EE12-FAED-47CF-922B-A3E14CCF697DQ34453174-7A9A8305-253C-4696-9FAF-869486555813
P2860
Clonal competition with alternating dominance in multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clonal competition with alternating dominance in multiple myeloma.
@ast
Clonal competition with alternating dominance in multiple myeloma.
@en
type
label
Clonal competition with alternating dominance in multiple myeloma.
@ast
Clonal competition with alternating dominance in multiple myeloma.
@en
prefLabel
Clonal competition with alternating dominance in multiple myeloma.
@ast
Clonal competition with alternating dominance in multiple myeloma.
@en
P2093
P2860
P50
P1433
P1476
Clonal competition with alternating dominance in multiple myeloma
@en
P2093
A Keith Stewart
Angela S Baker
Esteban Braggio
Jan B Egan
John D Carpten
Marta Chesi
Michael Barrett
P Leif Bergsagel
Patrick R Blackburn
Scott Van Wier
P2860
P304
P356
10.1182/BLOOD-2012-01-405985
P407
P577
2012-04-12T00:00:00Z